IntegriChain Appoints Experienced High-Growth Finance Executive as CFO
IntegriChain, a leading provider of revenue optimization technology for the pharmaceutical industry, has appointed Matt Heyman as its new Chief Financial Officer. Heyman brings over a decade of experience in corporate finance, strategy, and M&A, primarily in software businesses. CEO Josh Halpern expressed enthusiasm about Heyman joining the team, highlighting the company's focus on helping pharma innovators develop and implement sustainable growth strategies.
Heyman's appointment comes at a pivotal moment for IntegriChain, as the company aims for significant growth in the coming years. The new CFO expressed excitement about joining the leadership team and helping IntegriChain execute its vision both organically and inorganically. He emphasized the company's unique position in combining data, technology, outsourcing, and consulting to address drug commercialization challenges in today's market.
IntegriChain, un fornitore leader di tecnologie per l'ottimizzazione dei ricavi nel settore farmaceutico, ha nominato Matt Heyman come nuovo Chief Financial Officer. Heyman porta con sé oltre un decennio di esperienza in finanza aziendale, strategia e fusioni e acquisizioni, principalmente nel settore del software. Il CEO Josh Halpern ha espresso entusiasmo per l'ingresso di Heyman nel team, evidenziando l'attenzione dell'azienda nell'aiutare gli innovatori farmaceutici a sviluppare e implementare strategie di crescita sostenibili.
La nomina di Heyman avviene in un momento cruciale per IntegriChain, poiché l'azienda punta a una crescita significativa nei prossimi anni. Il nuovo CFO ha espresso entusiasmo per entrare a far parte del team di leadership e per aiutare IntegriChain a realizzare la sua visione sia in modo organico che inorganico. Ha sottolineato la posizione unica dell'azienda nel combinare dati, tecnologia, outsourcing e consulenza per affrontare le sfide della commercializzazione dei farmaci nel mercato attuale.
IntegriChain, un proveedor líder de tecnología para la optimización de ingresos en la industria farmacéutica, ha nombrado a Matt Heyman como su nuevo Director Financiero. Heyman aporta más de una década de experiencia en finanzas corporativas, estrategia y fusiones y adquisiciones, principalmente en negocios de software. El CEO Josh Halpern expresó su entusiasmo por la incorporación de Heyman al equipo, destacando el enfoque de la empresa en ayudar a los innovadores farmacéuticos a desarrollar e implementar estrategias de crecimiento sostenibles.
El nombramiento de Heyman llega en un momento clave para IntegriChain, ya que la compañía busca un crecimiento significativo en los próximos años. El nuevo CFO expresó su emoción por unirse al equipo de liderazgo y ayudar a IntegriChain a ejecutar su visión tanto de manera orgánica como inorgánica. Destacó la posición única de la empresa en la combinación de datos, tecnología, subcontratación y consultoría para abordar los desafíos de la comercialización de medicamentos en el mercado actual.
IntegriChain는 제약 산업을 위한 수익 최적화 기술의 선도적인 제공업체로, Matt Heyman을 새로운 최고 재무 책임자로 임명했습니다. Heyman은 주로 소프트웨어 기업에서 기업 재무, 전략, M&A 분야에서 10년 이상의 경험을 가지고 있습니다. CEO Josh Halpern은 Heyman이 팀에 합류하게 되어 기쁘다고 전하며, 제약 혁신가들이 지속 가능한 성장 전략을 개발하고 구현하는 데 도움을 주고자 하는 회사의 초점을 강조했습니다.
Heyman의 임명은 IntegriChain에게 중대한 시점에 이루어졌습니다. 이 회사는 향후 몇 년 동안 중대한 성장을 목표로 하고 있습니다. 새로운 CFO는 리더십 팀에 합류하게 되어 기쁘고, IntegriChain이 유기적 및 비유기적으로 비전을 실행하는 데 도움을 주고 싶다고 밝혔습니다. 그는 데이터를 기술, 아웃소싱, 컨설팅과 결합하여 오늘날의 시장에서 의약품 상용화 과제를 해결하는 회사의 독특한 입지를 강조했습니다.
IntegriChain, un fournisseur leader de technologies pour l'optimisation des revenus dans l'industrie pharmaceutique, a nommé Matt Heyman comme nouveau Directeur Financier. Heyman apporte plus d'une décennie d'expérience en finance d'entreprise, stratégie et fusions-acquisitions, principalement dans le secteur des logiciels. Le PDG Josh Halpern a exprimé son enthousiasme concernant l'arrivée de Heyman dans l'équipe, en soulignant l'importance pour l'entreprise d'aider les innovateurs pharmaceutiques à développer et à mettre en œuvre des stratégies de croissance durables.
La nomination de Heyman intervient à un moment décisif pour IntegriChain, alors que l'entreprise vise une croissance significative dans les années à venir. Le nouveau Directeur Financier a exprimé son enthousiasme à l'idée de rejoindre l'équipe de direction et d'aider IntegriChain à réaliser sa vision de manière organique et inorganique. Il a souligné la position unique de l'entreprise combinant données, technologie, externalisation et conseil pour répondre aux défis de la commercialisation des médicaments sur le marché actuel.
IntegriChain, ein führender Anbieter von Technologien zur Umsatzoptimierung in der pharmazeutischen Industrie, hat Matt Heyman zum neuen Chief Financial Officer ernannt. Heyman bringt über ein Jahrzehnt an Erfahrung in Unternehmensfinanzen, Strategie sowie Fusionen und Übernahmen mit, hauptsächlich im Softwarebereich. CEO Josh Halpern äußerte sich begeistert über Heymans Eintritt ins Team und hob den Fokus des Unternehmens hervor, pharmazeutischen Innovatoren zu helfen, nachhaltige Wachstumsstrategien zu entwickeln und umzusetzen.
Heymans Ernennung erfolgt zu einem schicksalhaften Moment für IntegriChain, da das Unternehmen in den kommenden Jahren signifikantes Wachstum anstrebt. Der neue CFO zeigte sich erfreut über seinen Eintritt in das Führungsteam und darüber, IntegriChain dabei zu unterstützen, seine Vision sowohl organisch als auch anorganisch umzusetzen. Er betonte die einzigartige Position des Unternehmens, Daten, Technologie, Outsourcing und Beratung zu kombinieren, um die Herausforderungen der Arzneimittelvermarktung auf dem heutigen Markt anzugehen.
- Appointment of experienced CFO with over a decade of relevant experience
- Company poised for significant growth in the coming years
- Strong focus on helping pharma innovators develop sustainable growth strategies
- Unique platform combining data, technology, outsourcing, and consulting for drug commercialization
- None.
"IntegriChain is poised for significant growth in the coming years as we focus on our mission – to help pharma innovators develop, implement, and operate sustainable growth strategies for life-changing science," said Josh Halpern, Co-Founder and CEO of IntegriChain. "We are thrilled to have Matt join us with his depth of experience in corporate finance and development, growing SaaS companies, and partnering with strategic investors."
"I am excited to join the IntegriChain leadership team at this pivotal moment," said Heyman. "The company has developed into a leading platform that uniquely combines data, technology, outsourcing, and consulting to address the essential challenges of drug commercialization in today's market. I look forward to helping IntegriChain execute its vision organically and inorganically as we continue to build out the ICyte Platform and arm our pharma customers with the keys they need to deliver renewed growth."
About Matt Heyman
Heyman will be responsible for IntegriChain's Global Finance and Accounting operations. He previously held numerous leadership roles at Diligent Corporation over the last eight years, most recently as the Senior Vice President, Finance and Corporate Development. During his tenure at Diligent, revenue increased fivefold, and he led numerous strategic acquisitions. Prior to Diligent, Heyman served on the corporate development team at the SaaS business Fleetmatics (NYSE:FLTX) through a successful acquisition by Verizon. He began his career in the investment banking and management consulting industries. Heyman earned a BA degree in economics from The George Washington University.
About IntegriChain
IntegriChain helps pharma manufacturers bring their science to market, ensuring patients have affordable, timely, and sustainable access to therapy. IntegriChain delivers Pharma's only data-driven commercialization platform — from strategy to operational execution. The Company's unique focus on data, technology, consulting, and outsourcing helps connect the commercial, financial, and operational dimensions of drug access and profitability. Through the ICyte Platform, IntegriChain enables pharmaceutical innovators to achieve better commercial outcomes by digitalizing daily and recurring business activities and by integrating data and operations across contracting, pricing, channel and distribution, and gross-to-net. IntegriChain is backed by Nordic Capital, a leading sector-specialized private equity investor with a broad portfolio in Healthcare and Technology. IntegriChain's umbrella of companies include Blue Fin Group and Federal Compliance Solutions, and the company is headquartered in
Contact
Jennifer Guinan | Sage Strategic Marketing | jennifer@sagestrat.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/integrichain-appoints-experienced-high-growth-finance-executive-as-cfo-302225806.html
SOURCE IntegriChain
FAQ
Who is the new CFO of IntegriChain?
What experience does Matt Heyman bring to IntegriChain?
What is IntegriChain's main focus according to the press release?
How does IntegriChain describe its platform in the pharmaceutical industry?
